関連する実験動画
Updated: Sep 9, 2025

05:46
Ultrasonic-Assisted Extraction of Cannabidiolic Acid from Cannabis Biomass
Published on: May 27, 2022
6.3K
カンナビディオルの生物利用性を向上させる:アモルフなカンナビディオルの粉末成分の開発と評価
Hiroki Aoyama1, Tatsuya Ogawa1, Hitomi Ozawa-Umeta1
1Therabiopharma Inc.
Journal of nutritional science and vitaminology
|August 31, 2025
まとめ
研究者は低生物利用性を克服するために無形なカンナビジオール (CBD) 粉末を開発しました. この改良された製剤はCBDの吸収を大幅に増加させ,食品やサプリメントでの使用を改善する道を開きます.
科学分野:
- 薬理学について
- 材料科学
背景:
- カンナビディオール (CBD) は,抗酸化,抗炎症,抗不安剤などの多くの有益な性質を持っています.
- CBDの臨床用途は,その固有の低い経口生物利用性が妨げられています.
- CBDの治療的可能性を高めるには 先進的な投与システムの開発が不可欠です
研究 の 目的:
- 改善された生物利用性を有する無形なカンナビジオール (CBD) 粉末製剤を開発する.
- ネズミにおける無形CBD製剤の薬動プロフィールを評価する.
- 異なるポリマーのCBD吸収への影響を評価する.
主な方法:
- アモルフなCBD粉は,食品グレードの溶媒シフト法で製造された.
- アモルフ製剤 (F3とPVP,F4とHPMC) と結晶CBD単離剤を比較したSprague- Dawleyラットでの薬理学研究が行われました.
- Cmax,AUC0- 6h,Tmaxを含む主要な薬理学パラメータを分析した.
主要な成果:
- アモルフなCBD製剤は,結晶CBDと比較して有意に生物利用性が向上した.
- Cmaxは3. 9倍 (F3) と3. 0倍 (F4) 増加した.
- AUC0- 6h値は5. 3倍 (F3) と5. 2倍 (F4) 高く,Tmaxは著しく低下した.
結論:
- 開発された無形CBD粉末製剤は優れた生物利用性を示しています.
- PVPやHPMCのようなポリマーの使用はCBDの吸収を効果的に促進する.
- 食品やサプリメントにおけるCBDの有効性を高めるため,この配合は有望である.
関連する概念動画
Factors Influencing Drug Absorption: Pharmaceutical Parameters
192
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
192
Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism
399
Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
399
Factors Influencing Drug Absorption: Physicochemical Parameters
429
The physicochemical characteristics of drugs play a crucial role in formulating stable and bioavailable drug products. The solubility of a drug, governed by the varying pH along the GI tract and its dissociation constant (pKa), is pivotal in determining its ionization state and absorption rate. Notably, weak acids and bases remain unionized and are absorbed more rapidly.
Enhanced drug absorption can be achieved by reducing particle sizes and increasing surface areas, thereby facilitating...
Enhanced drug absorption can be achieved by reducing particle sizes and increasing surface areas, thereby facilitating...
429
Biopharmaceutics and Pharmacokinetics: Overview
2.5K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
2.5K
Factors Affecting Dissolution: Particle Size and Effective Surface Area
1.0K
Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are...
1.0K
Bioequivalence: Overview
1.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.2K

